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Macrophage activation syndrome (MAS) is a potentially fatal condition. It belongs to the hemophagocytic lymphohistiocytosis
group of diseases. In adults, MAS is rarely associated with systemic lupus erythematosus, but it also arises as complication of
several systemic autoimmune disorders, like ankylosing spondylitis, rheumatoid arthritis, and adult-onset Still’s disease. Several
treatment options for MAS have been reported in the literature, including a therapeutic regimen of etoposide, dexamethasone, and
cyclosporine. Here we report a case of 42-year-old woman in whomMAS occurred as onset of systemic lupus erythematosus.
1. Introduction
Macrophage activation syndrome (MAS) is a potentially fatal
condition. It is a rare complication of several autoimmune
disorders, including systemic lupus erythematosus (SLE) and
systemic juvenile idiopathic arthritis (sJIA). The incidence of
MAS associated with SLE is about 0.9–4.6% [1]. MAS is a
multifarious disease, presenting with several signs and symp-
toms, including high fever, hepatomegaly, splenomegaly,
hemorrhagic manifestations (e.g., purpura), and dysfunction
of the central nervous system, like lethargy. Furthermore,
MAS is characterized by several alterations in laboratory tests,
including pancytopenia, hypofibrinogenemia, hypertriglyc-
eridemia, and hyperferritinemia.
MAS is classified among the group of hemophagocytic
lymphohistiocytosis (HLH), which includes familial HLH
and secondary HLH. Secondary HLH is triggered by sev-
eral causes, including infection, drugs, malignancy, and
rheumatic disorder [2].
We report a rare case of MAS that occurred as first
manifestation of SLE treated with high dose intravenous
methylprednisolone and oral cyclosporine.
2. Report of Case
A previously healthy 42-year-old Caucasian woman was
admitted to our department presenting an 8-week history
of persistent fever up to 39∘C with shiver unresponsive
to antipyretics, dyspnea, weight loss, malaise, and lethargy.
Her medical past history was unremarkable for rheumatic
diseases, severe infections, or immunodeficiency. Her family
history also was negative for rheumatic diseases.
Our clinical examination showed lymphadenopathy in
the axillae, a widespread rash prominent on her lower legs,
symmetric arthritis involving hands and wrists, and bilateral
pulmonary basal crackles.
We started instrumental and laboratory tests to rule
out the presence of autoimmune, infectious, or neoplastic
disease. Repeated blood and urine cultures and a thorough
infection screen including a viral panel for herpes zoster,
herpes simplex (HSV-1, HSV-2), Epstein-Barr virus (EBV),
cytomegalovirus, hepatitis B and C, HIV, coxsackie, and par-
vovirus B19 viruses were negative. The tuberculin sensitivity
test (PPD test) was negative.
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Laboratory routine showed pancytopenia, hypergamma-
globulinemia, hyperferritinemia (1700mg/dL), hypofibrino-
genemia (100mg/dL), hypertriglyceridemia (300mg/dL),
and raised levels of alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), 𝛾-glutamyl transferase, lactate
dehydrogenase, and serum creatinine. The levels of blood
urea nitrogen and total bilirubin were within reference range.
We also repeated ESR every five days, founding a progressive
reduction in levels, ranging from 120mm/h to 2mm/h.
Immunological screening was positive for ANA
(1 : 240 homogenous), anti-dsDNA (40UI/mL), anti-Sm
(154.56UI/mL), and anti-RNP (154.21 UI/m). Serum C3
and C4 complement factors were low, respectively, 0.43 g/L
(range 0.65–1.65 g/L) and 0.07 g/L (range 0.16–0.6 g/L).
We performed an abdominal ultrasound exam, founding
a moderate hepatosplenomegaly. Echocardiography revealed
a diffuse pericardial effusion without valvular vegetations,
oscillating intracardiac mass, abscess, or valvular regurgita-
tion. Chest CT examination showed a right-basal parenchy-
mal thickening, a bilateral pleural effusion, and multiple
mediastinal and axillary lymphadenopathy. Bronchoalveolar
lavage revealed neutrophils and bronchial cells smears with
squamousmetaplasia but excluded the presence of neoplastic
cells. Total lymphocyte count and CD4+/CD8+ T lymphocyte
ratio on bronchoalveolar lavage ruled out sarcoidosis. We
also performed an axillary lymph node biopsy, which was
negative for malignant lymphoproliferative disorder, and a
bone marrow biopsy, which detected hemophagocytosis.The
presence of pancytopenia, polyarthritis, pleural and pericar-
dial effusion, and positive ANA, anti-dsDNA, and anti-Sm
suggested a diagnosis of LES, according to the Systemic Lupus
International Collaborating Clinics (SLICC) classification
criteria [3]. At the same time, the particular evolution of the
ESR in association with the evidence of hemophagocytosis
in the bone marrow and the exclusion of infection led us to
themain diagnosis ofMAS, according to the hemophagocytic
lymphohistiocytosis (HLH) criteria as follows [2].
HLH criteria (at least 5 criteria should be met for MAS
diagnosis)
temperature ≥38.5∘C for 7 days at least,
spleen enlargement,
hypertriglyceridemia (>160mg/dL),
hypofibrinogenemia (<150mg/dL),
ferritin ≥500𝜇g/L,
hepatitis,
sIL-2 receptor >2400 IU/mL,
decreased or absent NK cell activity,
hemophagocytic cells in bone marrow, spleen, or
lymph nodes,
cytopenia in 2 ormore cell lines (hemoglobin<9 g/dL,
platelets <100 000/𝜇L, or neutrophils <1000/𝜇L).
We started high-dose intravenous methylprednisolone
(1 g/day) for three days. Then the drug was switched to
oral prednisolone 60mg and cyclosporine 3mg/kg daily.
After the end of methylprednisolone therapy, the patient was
apyretic; subsequently skin rash disappeared. The laboratory
parameters returned to normal levels within 2 weeks. The
patient was discharged from the hospital and is now under
follow-up at the outpatient clinic.
3. Discussion
MAS belongs to the group of hemophagocytic lymphohistio-
cytosis (HLH), which includes familial HLH and secondary
HLH. The association between HLH and autoimmune or
autoinflammatory disease is formally called MAS [4]. MAS
is commonly associated with sJIA [4] but has also been
reported in Kawasaki disease, adult-onset Still’s disease,
rheumatoid arthritis, Sjo¨gren’s syndrome, dermatomyositis,
mixed connective tissue disease, systemic sclerosis, and SLE
[5]. MAS associated with SLE is rare and the incidence is
about 0.9–4.6% [1]. To date, only 26 cases ofMAS only related
to the onset of SLE are reported in the literature [5–8].Wefind
other several cases of MAS due to SLE in the literature, but
these cases are related to SLE flare-up or complication [5, 9].
The diagnosis of MAS is a challenge. Indeed, the clinical
features of MAS-associated SLE and active SLE are very
similar. In a recent paper it is reported that respiratory
symptoms, jaundice, and lymphadenopathy are present in
75% of patients [10]. However, hyperferritinemia is reputed
the best parameter to discriminate between MAS-associated
SLE and active SLE with a sensitivity and specificity of almost
100% [1]. Nevertheless, severe leukopenia leads the clinician
to evaluate the presence of MAS [11]. In our patient, the
diagnosis of MAS-associated SLE was made according to
HLH-2004 criteria (see HLH criteria) [2].
To date, the pathogenesis of MAS is not totally known.
It is considered an intensive systemic inflammatory reac-
tion, caused by a massive dysregulation of macrophage–
lymphocyte interactions, which provokes increases in the
levels of several cytokines, particularly TNF-𝛼, M-CSF recep-
tors, interleukin- (IL-) 1, IL-6, and interferon gamma- (IFN-)
𝛾 [12].
Index of suspicion for MAS is higher when an infection
is ruled out or inflammation persists and does not respond
to treatment of an underlying infection. In this case, it could
be useful to start an immunomodulatory therapy even in
the face of infection. To date, several therapeutic options
are available, including nonbiologic and biologic treatments.
The cornerstone is represented by steroids. An intravenous
methylprednisolone pulse therapy (e.g., 30mg/kg for three
consecutive days) followed by 2-3mg/kg per day is the
most common schedule [2]. However, several drugs are
used alone or in combination to reduce steroids. Parenteral
administration of cyclosporine A (CSA) (2–7mg/kg/day)
is usually started if methylprednisolone lacks improvement
[13]. In addition, CSA is used after the discharge of patients
to maintain MAS under control [1]. In patients unresponsive
to steroids and CSA, HLH-2004 treatment protocol could be
useful [5]. This protocol includes dexamethasone, CSA, and
etoposide. However, the potential liver toxicity of etoposide
restricts the use of this therapeutic option. Recently, Coca et
al. reported the use of antithymocyte globulin (ATG) as an
Case Reports in Medicine 3
alternative to etoposide [14], but infusion reactions to ATG
are commonly described in the literature [15]. Although some
authors reported the development of HLH after adminis-
tration of TNF-𝛼 antagonist [16, 17], infliximab could be a
useful treatment in refractory cases of MAS [18]. Rituximab
[19] and intravenous immunoglobulin (IVIG) [20] have been
employedwith good results inMAS triggered by viruses, such
as EBV or cytomegalovirus. In the pediatric community, IL-1
blockers had become almost standard of care for treatment of
MAS regardless of underlying autoimmune disorder [21–25],
although the role of IL-1 in the pathogenesis of MAS is still
only partially known. However, some authors reported some
cases of MAS possibly triggered by anakinra [24, 25].
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